Diabetes News

This study provides tools to predict premature mortality in type 2 diabetic inpatients (International Journal of Clinical Practice)

As used in current clinical practice to treat hyperglycaemia in acute coronary syndromes, IVII appears to be of benefit only for patients with STEMI who are not known to have diabetes. IVII is associated with adverse early outcomes in patients with NSTEMI (European Heart Journal – Cardiovascular Care)

The benefits with respect to mortality that had been observed among patients originally assigned to blood-pressure–lowering therapy were attenuated but still evident at the end of follow-up. There was no evidence that intensive glucose control during the trial led to long-term benefits with respect to mortality or macrovascular events (NEJM)

In adults with type 1 diabetes, fasting TG independently predicted cardiorenal disease over 6 years and improved reclassification of risk by conventional risk factors (Journal of Clinical Lipidology)

In our population-based study, incretin-based drug use was not associated with an increased risk of CHF among patients with type 2 diabetes (Diabetes Care)

Patients with diabetes admitted for chest pain with HbA1c less than 6.5% may be at increased risk for in-hospital and 1-year mortality. The mechanism for death may be mediated in part by hypoglycemia (Cardiovascular Endocrinology)

In this study 34% of the participants had diabetes, Results: LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure (NEJM)

PN is associated with increased risk for a first cardiovascular event among individuals with diabetes (Heart)

In our patient population, HbA1c scores

Metformin use was associated with a decreased risk of AF in patients with type 2 DM who were not using other anti-diabetic medication, probably via attenuation of atrial cell tachycardia-induced myolysis and oxidative stress (Cardiovascular Diabetology)

This new CHD risk estimator has better discriminative ability for incident CHD than the FRS, UKPDS, and the ATP III/NCEP recommendations in a multi-ethnic cohort with T2DM (Atherosclerosis)

Our findings suggest that ASA utilization for primary prevention in diabetic patients causes a significant increase of oxidative stress burden impairing the vascular function. Present data, if confirmed on a larger population, could permanently discourage the use of the ASA for the primary prevention in patients with DM (Acta Diabetologica)

The current study suggests a U-shaped association between observed BP and the risk of HF among diabetic patients (International Journal of Cardiology)

Sitagliptin use was not associated with an increased risk of all-cause hospitalizations or death, but was associated with an increased risk of HF-related hospitalizations among patients with T2D with pre-existing HF (JACC)

Increased GV promoting hypoglycemic stress was associated with reduced HRV independent of glycemic control as assessed by HbA1c. These pilot data suggest that glucose variability may contribute to cardiovascular autonomic dysfunction among adults with type 1 diabetes (Diabetes Care)

In patients with type 2 diabetes without ischemic heart disease, a high intake of polyunsaturated fatty acids, especially alpha linolenic acid, was protective for the development of cardiac events (Atherosclerosis)

Myocardial copper deficiency and defective cellular copper transport/trafficking are revealed as key molecular defects underlying LV impairment in diabetes, and TETA-mediated restoration of copper regulation provides a potential new class of therapeutic molecules for DCM (Cardiovascular Diabetology)

High plasma AGEs were associated with incident cardiovascular events in individuals with T2DM. These results underline the potential importance of AGEs in development of CVD (Diabetes)

Intensified insulin-based glycaemic control after acute myocardial infarction in patients with diabetes and hyperglycaemia at admission had a long-lasting effect on longevity (The Lancet Diabetes & Endocrinology)

This study suggests that calpain may play a role in vascular endothelial cell ROS production and endothelium-dependent dysfunction in diabetes. Thus, calpain may be an important therapeutic target to overcome diabetes-induced vascular dysfunction (Cardiovascular Diabetology)